CEO Clive Meanwell detailed plans to deploy a 400-person commercial group in the U.S. to target 1,100 leading hospitals in the U.S.
As The Medicines Co. prepares to launch a string of newly approved products in 2015, the company is putting the commercial team in place to target the top hospitals in the U.S. across the product groups, CEO Clive Meanwell said during the company’s first quarter sales and earnings call May. 5.
“As we enter this phase of multiple drug launches in the U.S., we are deploying approximately 400 people to work with our customers, which comprise about 1,100 leading hospitals in the U.S.,” he said
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
A professional slide deck for the drospirenone/estetrol oral contraceptive inappropriately suggests it is safer than other estrogen-containing products and understates risks, Office of Prescription Drug Promotion said in the first “untitled” letter issued since reductions-in-force.
Silicon Valley investor Jim O’Neill’s Senate confirmation hearings showcased the unique background of someone with government and tech experience and avoided discussions of his past statements about lowering the bar for regulatory approval.
The FDA continues to wait for a decision on whether its priority guidances will be published as HHS asks the public for potential regulation cuts to fulfill President Trump’s executive order.
